Neurol. praxi. 2022;23(1):36-41 | DOI: 10.36290/neu.2021.064

Hereditary neuropathies in childhood

prof. MUDr. Pavel Seeman, Ph.D.
Klinika dětské neurologie, 2. LF UK a FN Motol, Praha

Hereditary neuropathies are a heterogeneous group of genetically determined peripheral nerve diseases. In the vast majority of patients, they occur by 20 years of age, most typically during school age between ages 6 and 15, and are manifested by slowly progressive muscle weakness distally and, later on, by atrophies, initially and more predominantly in the lower limbs, as well as by sensory disturbance of varying severity with a distal maximum, sometimes even by trophic changes. The onset of complaints with initial symptoms of the disease in preschool age or after 20 years of age is rarer, but also possible, and is, to a great degree, related to the particular gene disorder. Hereditary neuropathies are the most frequent genetically determined neuromuscular diseases, affecting approximately 4,000 people in the Czech Republic. Hereditary neuropathies do not reduce normal life expectancy, but may lead to physical disability with loss or substantial worsening of independent gait and significantly affect the quality of life as well as self-locomotion and self-care. The intellectual level is typically normal. The severity of disability largely depends on the genetic cause as well as on disease duration.

Keywords: hereditory neuropathy, neurogenetics, Charcot-Marie-Tooth, HMSN, CMT, neuropediatrics.

Received: August 10, 2021; Revised: September 1, 2021; Accepted: September 1, 2021; Prepublished online: September 1, 2021; Published: March 14, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Seeman P. Hereditary neuropathies in childhood. Neurol. praxi. 2022;23(1):36-41. doi: 10.36290/neu.2021.064.
Download citation

References

  1. Baránková L, Vyhnálková E, Züchner S, et al. GDAP1 mutations in Czech families with early-onset CMT. Neuromuscular Disorders. 2007;17:482-489. Go to original source... Go to PubMed...
  2. Brožková DŠ, Posádka J, Laššuthová P, et al. Spectrum and frequencies of mutations in the MFN2 gene and its phenotypical expression in Czech hereditary motor and sensory neuropathy type II patients. Mol Med Rep. 2013;8(6):1779-1784. Go to original source... Go to PubMed...
  3. Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet. 2020;5:473-481. Go to original source... Go to PubMed...
  4. Laššuthová P, Mazanec R, Vondráček P, et al. High frequency of SH3TC2 mutations in Czech HMSN I patients. Clin Genet. 2011;80(4):334-345. Go to original source... Go to PubMed...
  5. Laššuthová P, Sišková D, Haberlová J, et al. Congenital cataract, facial dysmorphism and demyelinating neuropathy (CCFDN) in 10 Czech Gypsy children - frequent and underestimated cause of disability among Czech Gypsies. Orphanet J Rare Dis. 2014;9:46. Go to original source... Go to PubMed...
  6. Laššuthová P, Šafka-Brožková D, Krůtová M, et al. Mutations in HINT1 are one of the most frequent causes of hereditary neuropathy among Czech patients and neuromyotonia is rather an undiagnosed symptom. Neurogenetics. 2015;16(1):43-54. Go to original source... Go to PubMed...
  7. Laššuthová P, Mazanec R, Staněk D, et al. Biallelic variants in the SORD gene are one of the most common causes of hereditary neuropathy among Czech patients. Scientific Reports. 2021;11:8443. Go to original source... Go to PubMed...
  8. Seeman P, Mazanec R, Čtvrtečková M, et al. CMT gonosomálně dominantní typ CMT1X - první nálezy mutací v genu pro Cx32 v České republice. Ces a Slov Neurol a Neurochir. 2000;63/96(4):219-225.
  9. Seeman P, Cíbochová R, Beneš jr. V, et al. Kongenitální hypomyelinizace v souvislosti s de-novo mutací genu pro PMP 22, 2001 - první prokázaný případ v ČR. Ces Slov Neurol Neurochir. 2002;65/98:206-212.
  10. Seeman P, Mazanec R, Horáček O, et al. Divergentní fenotypy choroby CMT: demyelinizační s infantilním začátkem a axonální s pozdním začátkem a zpomalenou fotoreakcí následkem různých mutací P0 genu. Ces Slov Neurol Neurochir. 2004;67/100:21-329.
  11. Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;12,64(7):1209-1214; a později její vylepšená verze CMTNSv.2 (Murphy et al., 2011) Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198. Go to original source... Go to PubMed...
  12. Šafka Brožková D, Haberlová J, Mazanec R, et al. HSMNR belongs to the most frequent types of hereditary neuropathy in the Czech Republic and is twice more frequent than HMSNL. Clin Genet. 2016;(90)2:161-165. Go to original source... Go to PubMed...
  13. Šafka Brožková D, Paulasová Schwabová J, Neupauerová J, et al. HMSN Lom in 12 Czech patients, with one unusual case due to uniparental isodisomy of chromosome 8. J Hum Genet. 2017;(62)3:431-435. Go to original source... Go to PubMed...
  14. Šafka Brožková D, Stojkovic T, Haberlová J et al. Demmyelinating Charcot-Marie-Tooth neuropathy associated with FBLN5 mulations. Eur J Neurol. 2020;12:2568-2574. Go to original source... Go to PubMed...
  15. Tao F, Beecham GW, Rebelo AP, et al. Modifier Gene Can­didates in Charcot-Marie-Tooth Disease Type 1A: A Case-Only Genome-Wide Association Study. J Neuromuscul Dis. 2019;6(2):201-211. Go to original source... Go to PubMed...
  16. Verhoeven K, Claeys KG, Züchner S, et al. MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. Brain. 2006;129(8):2093-2102. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.